-The Hindustan Times Raipur (Chhattisgarh): Eleven women have died and dozens more are in a critical condition after a government-run sterilisation programme in Chhattisgarh designed to control the country's billion-plus population went wrong, officials said on Tuesday. More than 50 women are seriously ill after suffering complications from the surgery in Bilaspur district over the weekend, authorities in Chhattisgarh said. "Reports of a drop in pulse, vomiting and other ailments started...

-The Hindu Is India ready to cash in on its demographic dividend? A demographic dividend is a once-in-a-lifetime opportunity for a nation and can either make or mar its citizens' present and future. When the share of the working-age population is on a rising curve while the share of dependents (those under the age of 15 and over 60) is falling, it enables workers to save (hence savings share in GDP rises)...

-Business Standard State expects more investment as industry cheers move Paving the way for the first set of labour reforms in the country, President Pranab Mukherjee has given his assent to Rajasthan's amendments to three laws. Among major changes, the Industrial Disputes Act will allow companies employing up to 300 staffers to lay off workers or close down without taking the government's prior approval. Earlier, those with up to 100 employees...

-The Hindu Terming death penalty a "cruel and barbaric" punishment used mainly against the "marginalised and poor", hundreds of eminent citizens, including Nobel laureate Amartya Sen, actor Aamir Khan, sociologist Andre Beteille, economist Jagdish Bhagwati and author Vikram Seth among others, issued a public statement on Sunday opposing the practice. Arguing that more than 70 per cent of the world's countries were abolitionist in law or practice, they said India "clings to...

-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...